Doug Langa | Source | Executive Vice President, North America Operations and President at Novo Nordisk

In his role at Novo Nordisk, Doug oversees US and Canadian operations encompassing more than 4,000 employees and representing more than half of the company’s global revenue. Under his leadership (2017-present), Novo Nordisk has launched five new products in the US (FIASP®, Rebinyn®, Ozempic®, Rybelsus® and Xultophy®), diversified its treatment areas and implemented a completely new operating model. Prior to that he spent five years in market access leadership positions with NNI where he reversed years of decline by rebuilding the Managed Market and Market Access departments into industry leaders for their function. Doug also held leadership positions at GSK and J&J prior to joining Novo Nordisk.